Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Cancer Research

• Publication date

  1997-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 9331099
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells.

  1996cited by this paper
• Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer.

  1996cited by this paper
• Integrated map of the chromosome 8p12-p21 region, a region involved in human cancers and Werner syndrome.

  1996cited by this paper
• Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors

  1996cited by this paper
• Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer.

  1996cited by this paper
• Molecular cytogenetic characterization and physical mapping of 12q13–15 amplification in human cancers

  1996cited by this paper
• Hybrid selection of transcribed sequences from microdissected DNA: isolation of genes within amplified region at 20q11-q13.2 in breast cancer.

  1996cited by this paper
• DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours.

  1996cited by this paper
• Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17.

  1995cited by this paper
• E2F-4 and E2F-5, two members of the E2F family, are expressed in the early phases of the cell cycle.

  1995cited by this paper
• Genetic alterations in breast cancer

  1995cited by this paper
• Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications.

  1995cited by this paper
• Characterization of the region of the short arm of chromosome 8 amplified in breast carcinoma.

  1995cited by this paper
• Patterns of dna amplification at band q13 of chromosome 11 in human breast cancer

  1994cited by this paper
• Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes.

  1994cited by this paper
• Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice

  1994cited by this paper
• Somatic genetic changes in human breast cancer.

  1994influential reference
• Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2.

  1994cited by this paper
• Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization.

  1994influential reference
• Molecular cytogenetics of human breast cancer.

  1994cited by this paper
• CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1.

  1994cited by this paper
• Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.

  1994cited by this paper
• Cyclin E, a potential prognostic marker for breast cancer.

  1994cited by this paper
• Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2.

  1993cited by this paper
• Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts.

  1993cited by this paper
• Deregulation of cyclins D1 and E and suppression of cdk2 and cdk4 in senescent human fibroblasts.

  1993cited by this paper
• The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is located in cell-substratum contact sites

  1993cited by this paper
• FGFRI and PLAT genes and DNA amplification at 8p 12 in breast and ovarian cancers

  1993cited by this paper
• Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21.

  1993cited by this paper
• Mapping the whole human genome by fingerprinting yeast artificial chromosomes.

  1992cited by this paper
• Localization of 11q13 loci with respect to regional chromosomal breakpoints.

  1992cited by this paper
• Isolation, characterization and chromosomal localization of the human GADD153 gene.

  1992cited by this paper
• DNA amplification at 11q13 in human cancer: from complexity to perplexity.

  1992cited by this paper
• Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas.

  1992cited by this paper
• BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers.

  1991cited by this paper
• Identification and cloning of a novel amplified DNA sequence in human malignant fibrous histiocytoma derived from a region of chromosome 12 frequently rearranged in soft tissue tumors.

  1991cited by this paper
• BCL-1 participates in the 11q13 amplification found in breast cancer.

  1990cited by this paper
• Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer.

  1990cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast cancer.

  1990cited by this paper
• Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma.

  1989cited by this paper
• Proto-oncogene amplification and human breast tumor phenotype.

  1989cited by this paper
• HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer.

  1989cited by this paper
• Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors.

  1989cited by this paper
• Human N-myc is closely related in organization and nucleotide sequence to c-myc

  1986cited by this paper
• The neu oncogene encodes an epidermal growth factor receptor-related protein

  1986cited by this paper
• Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma.

  1983cited by this paper
• AUTOMATIC INTERACTION DETECTION

  1982cited by this paper
• Human DNA sequence homologous to the transforming gene (mos) of Moloney murine sarcoma virus.

  1982cited by this paper

• Fibroblast growth factor receptor signaling modulates cholesterol storage in a SOAT1-dependent manner to promote mammary tumor cell invasion

  2025cites this paper
• YEATS4 reads histone crotonylation to promote fatty acid metabolism and cancer cell stemness.

  2025cites this paper
• Comparative analysis of hybrid-SNP microarray and nanopore sequencing for detection of large-sized copy number variants in the human genome

  2025cites this paper
• Oncogenic mutations of clinical significance in colorectal cancer.

  2025cites this paper
• Targeting CDK4 and CDK6 in hormone-dependent cancers.

  2025cites this paper
• CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer

  2025cites this paper
• The regulatory role of CDK4/6 inhibitors in tumor immunity and the potential value of tumor immunotherapy (Review)

  2025cites this paper
• Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first‐in‐human phase I study

  2024cites this paper
• Receptor tyrosine kinases in breast cancer treatment: unraveling the potential.

  2024cites this paper
• Prostate Cancer: Advances in Genetic Testing and Clinical Implications

  2023cites this paper
• Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors

  2023cites this paper
• To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors.

  2023cites this paper
• Nebivolol Sensitizes BT-474 Breast Cancer Cells to FGFR Inhibitors

  2023cites this paper
• Targeting cyclin D1 as a therapeutic approach for papillary thyroid carcinoma

  2023cites this paper
• Systematic pharmacological analysis of agonistic and antagonistic fibroblast growth factor receptor 1 MAbs reveals a similar unique mode of action

  2022cites this paper
• Development of resistance to FGFR inhibition in urothelial carcinoma via multiple pathways in vitro

  2022cites this paper
• Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status

  2022cites this paper
• Exploring the FGF/FGFR System in Ocular Tumors: New Insights and Perspectives

  2022cites this paper
• Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors

  2022cites this paper
• Fibroblast growth factor receptor 1 protein (FGFR1) as potential prognostic and predictive marker in patients with luminal B breast cancers overexpressing human epidermal receptor 2 protein (HER2)

  2021cites this paper
• Tumor Suppressor Effect of RBMS3 in Breast Cancer

  2021cites this paper
• FGFR1 copy number in breast cancer: associations with proliferation, histopathological grade and molecular subtypes

  2021cites this paper
• Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling

  2021cites this paper
• Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer

  2021cites this paper
• Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer

  2020cites this paper
• Towards More Powerful Antibodies for Fibroblast Growth Factor Receptors in Breast Cancer

  2020cites this paper
• The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments

  2020cites this paper
• The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments

  2020cites this paper
• Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling.

  2020cites this paper
• Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients

  2020cites this paper
• Unbiased Detection of Driver Mutations in Extramammary Paget Disease

  2020cites this paper
• DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo

  2020cites this paper
• Implicaciones de la inestabilidad cromosómica y heterogeneidad clonal en la respuesta a la terapia en cáncer de seno

  2019cites this paper
• Detection of actionable mutations in ctDNA in advanced breast cancer patients

  2019cites this paper
• Amplicons in breast cancers analyzed by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.

  2019cites this paper
• Comprehensive Gene Expression Analysis in NMIBC Using RNA-seq Reveals New Therapy Strategies

  2019cites this paper
• Cyclin D1 overexpression in Algerian breast cancer women: correlation with CCND1 amplification and clinicopathological parameters

  2019cites this paper
• A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer

  2019cites this paper
• FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer

  2019cites this paper
• Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer

  2019cites this paper
• New Treatments for Metastatic Breast Cancer

  2018cites this paper
• C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis

  2018cites this paper
• A novel structural fucosylated chondroitin sulfate from Holothuria Mexicana and its effects on growth factors binding and anticoagulation.

  2018cites this paper
• FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis

  2018cites this paper
• FGFR3 mRNA overexpression defines a subset of oligometastatic colorectal cancers with worse prognosis

  2018cites this paper
• Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer

  2018cites this paper
• RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade

  2018cites this paper
• FGFR3-Überexpression ist eine relevante Alteration in kolorektalen Karzinomen

  2018cites this paper
• Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges

  2018cites this paper
• Pazopanib Sensitivity in a Patient With Breast Cancer and FGFR1 Amplification.

  2017cites this paper
• Changing Paradigms in the Management of Breast Cancer

  2017influential citation
• Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer

  2017cites this paper
• Targeting FGFR Pathway in Breast Cancer

  2017cites this paper
• Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach.

  2017cites this paper
• FGFR-targeted therapeutics for the treatment of breast cancer

  2017cites this paper
• Integrated analysis of differentially expressed genes and pathways in triple-negative breast cancer

  2017cites this paper
• Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

  2017cites this paper
• Title: Association of FGFR1 with ER  maintains ligand-independent ER transcription and 1 mediates resistance to estrogen deprivation in ER+ breast cancer 2

  2017cites this paper
• PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression

  2017cites this paper
• The Role of Chromosomal Instability in Cancer and Therapeutic Responses

  2017cites this paper
• A FGFR1 inhibitor patent review: progress since 2010

  2017cites this paper
• Advances and challenges in targeting FGFR signalling in cancer

  2017cites this paper
• Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study

  2017cites this paper
• Assessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors

  2016cites this paper
• Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape

  2016cites this paper
• Therapeutic uses of FGFs.

  2016cites this paper
• The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus

  2016cites this paper
• FGFR 1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma

  2016cites this paper
• Association between cyclin D1 G870A polymorphism and hepatocellular carcinoma risk: a meta-analysis

  2016cites this paper
• Myeloid-specific TGF-β signaling in bone promotes basic-FGF and breast cancer bone metastasis

  2016cites this paper
• Blocking the FGF/FGFR system as a "two-compartment" antiangiogenic/antitumor approach in cancer therapy.

  2016cites this paper
• FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma

  2016cites this paper
• Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application

  2016cites this paper
• The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study

  2016cites this paper
• Myeloid-speci fi c TGF-β signaling in bone promotes basic-FGF and breast cancer bone metastasis

  2016cites this paper
• Cell-free plasma markers of breast cancer in young women and women at high risk

  2016cites this paper
• Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low‐risk patient as defined by targeted sequencing

  2016cites this paper
• Whole Exome- and mRNA-Sequencing of an AT/RT Case Reveals Few Somatic Mutations and Several Deregulated Signalling Pathways in the Context of SMARCB1 Deficiency

  2015cites this paper
• Targeting Receptor Tyrosine Kinases in Cancer

  2015cites this paper
• Rationale for targeting fibroblast growth factor receptor signaling in breast cancer

  2015cites this paper
• Targeting FGFR Signaling in Cancer

  2015cites this paper
• Targeting fibroblast growth factor receptor pathway in breast cancer

  2015cites this paper
• Bioinformatics in Breast Cancer Research

  2015cites this paper
• Factors Promoting Tamoxifen Resistance in Breast Cancer via Stimulating Breast Cancer Stem Cell Expansion.

  2015cites this paper
• Dysregulation of FGFR Signaling in Human Malignancies

  2015cites this paper
• Cell-Cell Communication Networks Propose a Modulation of the Hematopoietic Stem Cell Niche by Invading Breast Carcinoma Cells

  2015cites this paper
• Functional genomics analysis reveals a MYC signature associated with a poor clinical prognosis in liposarcomas.

  2015cites this paper
• Development of Fibroblast Growth Factor Receptor Inhibitors: Kissing Frogs to Find a Prince?

  2015cites this paper
• FIBROBLAST GROWTH FACTOR RECEPTOR IN CANCER

  2015cites this paper
• Partial PTEN deletion is linked to poor prognosis in breast cancer

  2015cites this paper
• γKlotho is a novel marker and cell survival factor in a subset of triple negative breast cancers

  2015cites this paper
• FGFR1 Amplification Is Often Homogeneous and Strongly Linked to the Squamous Cell Carcinoma Subtype in Esophageal Carcinoma

  2015cites this paper
• The FGFR Receptor Family

  2015cites this paper
• Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy

  2015cites this paper
• Breast Cancer Genomics

  2014cites this paper
• Helicobacter pylori-induced STAT3 activation and signalling network in gastric cancer

  2014cites this paper
• Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.

  2014cites this paper
• Genetic Alterations of Chromosome 8 Genes in Oral Cancer

  2014cites this paper
• Clinical management of advanced gastric cancer: the role of new molecular drugs.

  2014cites this paper
• Identification of KSR1 as a novel target and decoding tyrosine kinase proteome in breast cancer

  2014cites this paper